GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2009

Cenix to Conduct RNAi-Based Target Discovery for Boehringer Ingelheim

  • Cenix BioScience will help Boehringer Ingelheim discover novel therapeutic drug targets. The firm will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in what will be a genome-scale screen using cultured human cells.

    Multiparametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement Boehringer Ingelheim’s assays to generate insights into the cellular functions and loss-of-function phenotypes of analyzed genes.

    Such RNAi datasets offer a highly predictive and cost-effective basis for mining the human genome to discover and prioritize targets for therapeutic drug development in a wide range of disease fields, according to Cenix.

    ---

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?